Sofosbuvir/Velpatasvir - A Promising Treatment for Chronic Hepatitis C Virus Infection.
and direct-acting antivirals agents
chronic hepatitis c virus
hcv hepatitis
ribavirin
sofosbuvir/velpatasvir
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
02
07
2021
accepted:
16
08
2021
entrez:
20
9
2021
pubmed:
21
9
2021
medline:
21
9
2021
Statut:
epublish
Résumé
Hepatitis C virus (HCV) infection is a disease that affects millions of people worldwide and has an enormous global public health impact. Chronic HCV is a long-term infection that goes unnoticed until the virus destroys the liver enough to induce liver disease symptoms. The inadequate and poorly tolerated treatment contributes to the burden of chronic HCV. Treatments have improved over time - direct-acting antivirals (DAAs) that targeted different hepatitis C virus genomic sites have shown to be more effective and well-tolerated. Patients recover to a greater extent following a treatment regimen based on DAAs. We conducted this literature review to investigate the effectiveness of these medications in treating chronic HCV infection. Relevant articles were identified by searching PubMed and Google scholar databases. Our primary goal was to analyze the efficacy and safety of the DAA, sofosbuvir plus velpatasvir, with or without ribavirin, in cirrhotic or non-cirrhotic, naïve or previously treated, chronic HCV patients. We found that treating patients with sofosbuvir-velpatasvir for 12 weeks was highly effective with fewer adverse events, including those with compensated cirrhosis. The outcomes aided in improving HCV treatment, lowering the disease's burden and fatality rate.
Identifiants
pubmed: 34540464
doi: 10.7759/cureus.17237
pmc: PMC8443867
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e17237Informations de copyright
Copyright © 2021, Ahmed et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Hepatol Int. 2018 Jul;12(4):356-367
pubmed: 30030720
J Gen Intern Med. 2018 Apr;33(4):551-557
pubmed: 29352420
Hepatology. 2002 Mar;35(3):704-8
pubmed: 11870387
Aliment Pharmacol Ther. 2014 Apr;39(7):686-98
pubmed: 24612116
N Engl J Med. 2015 Dec 31;373(27):2599-607
pubmed: 26571066
World J Hepatol. 2015 Apr 18;7(5):806-13
pubmed: 25914781
Pan Afr Med J. 2013;14:44
pubmed: 23560127
Clin Gastroenterol Hepatol. 2017 Mar;15(3):349-359
pubmed: 27840182
Oncotarget. 2017 Dec 29;9(4):5509-5513
pubmed: 29435197
Hepatology. 2014 Jul;60(1):98-105
pubmed: 24615981
N Engl J Med. 2015 Dec 31;373(27):2618-28
pubmed: 26569658
Can J Gastroenterol Hepatol. 2017;2017:6468309
pubmed: 28367429
J Gastrointestin Liver Dis. 2018 Jun;27(2):159-168
pubmed: 29922761
Acta Biomed. 2018 Oct 08;89(3):321-331
pubmed: 30333452
Hepatology. 2013 Apr;57(4):1333-42
pubmed: 23172780
Infect Drug Resist. 2019 Jul 23;12:2259-2268
pubmed: 31413603
Aliment Pharmacol Ther. 2008 Aug 15;28(4):397-404
pubmed: 18549461
J Infect Public Health. 2018 Mar - Apr;11(2):156-164
pubmed: 28970099
World J Gastroenterol. 2014 Aug 28;20(32):11033-53
pubmed: 25170193
Hepat Med. 2014 Apr 29;6:25-33
pubmed: 24822024
Am Fam Physician. 2015 Jun 15;91(12):835-42
pubmed: 26131943
PLoS One. 2019 Jul 18;14(7):e0219508
pubmed: 31318916
Daru. 2017 Apr 20;25(1):11
pubmed: 28427463
J Hepatol. 2017 Jan;66(1):153-194
pubmed: 27667367
Acta Biomed. 2019 May 23;90(2):187-196
pubmed: 31124995
Virology. 2015 May;479-480:221-33
pubmed: 25847726
World J Gastroenterol. 2016 Sep 14;22(34):7824-40
pubmed: 27678366
EClinicalMedicine. 2020 Jan 05;18:100237
pubmed: 31922124
BMC Infect Dis. 2017 Nov 16;17(1):722
pubmed: 29145802
J Viral Hepat. 2019 Jun;26(6):770-773
pubmed: 30663168